New York Law Journal
VOLUME 249—NO. 77 TUESDAY, April 23, 2013

Outside Counsel

A Tale of How Successfully Raising Capital Leads to Bankruptcy

By Morris N. Simkin,
Sandra Holtzman
And David Schmidt

   Neogenix Oncology was organized in 2004 when Dr. Ariel Hollinswhead, professor of medicine and head of the George Washington University Cancer Research Laboratory, assigned her research on developing therapeutic and diagnostic products to treat pancreatic, colon, lung, prostate and colorectal cancers to the company. Its efforts focused primarily on the development of therapeutic monoclonal antibodies targeted against pancreatic and colorectal cancer. To fund itself through the start-up and developmental stages it relied on the sale of its common stock to third parties. And this is where our tale of woe begins.1

   Between 2004 and 2011 Neogenix raised $47.1 million through the sale of shares using third-party finders who were not registered to sell stock either with the Securities and Exchange Commission or any state securities commission. These finders made a total of 83 placements and were paid $3.8 million.2

   But all of this had to surface. The Securities Exchange Act at the time required companies with over $10 million in assets and over 500 shareholders of record to register with the SEC and file quarterly and annual reports.

   Neogenix registered its stock with the SEC in April 2006. In its filings with the SEC, Neogenix disclosed these numerous sales of its common stock using finders.3

The JOBS Act doesn't really help the small companies seeking capital through private placements without the use of SEC-registered broker-dealers.

   In October 2011 the SEC's Philadelphia Regional Office wrote Neogenix asking for an explanation of its numerous sales of stock through the use of finders that were not SEC-registered broker-dealers.4 Under the Securities Exchange Act it is illegal to sell a company's common stock through the use of third parties that are not registered as broker-dealers with the SEC. Transactions in violation of the Securities Exchange Act can be voided by the party who did not violate the act. In addition, many state securities laws or "blue sky" laws provide a right of rescission to the buyer of securities sold by a finder that is not licensed under that state's securities laws. Neogenix may have had an inkling of this because in May 2011 it terminated its chief financial officer.

   This letter from the SEC caused great consternation at the company and with its accountants. How should they account for the possible liability since these various sales of common stock using finders could be rescinded? It took Neogenix and its accountants some six months to resolve this.5 Neogenix got the SEC's Chief Accountant's Office to agree that until suits were filed for rescission of these sales, it would disclose the sales in possible violation of the law as a footnote to its financial statement and estimate its contingent liability. In the footnotes to its Dec. 31, 2011, financial statements, Neogenix stated that no suits had been filed and estimated its contingent liability could be as much as $31 million. These same financial statements showed the company had total assets of $6,341,626 and a net worth of $4 million.

   With these disclosures their sources of capital dried up. They retained an investment banking firm in mid-2011 to raise capital. But with no success. They retained another investment banking firm in 2012 to advise them what to do—merge, sell to another company or reorganize under the Bankruptcy Code.6 Reorganizing under the Bankruptcy Code would allow the successor to Neogenix to take over the research that had been performed but without assuming any liability for the sales of shares using unregistered finders.7

   The end result was that Neogenix filed under Chapter 11 of the Bankruptcy Code, and sold itself to a company organized by several of its insiders. As a result of the bankruptcy process, the contingent liability of Neogenix from the sale of its stock using unlicensed finders was wiped out and was not assumed by the buyer of its assets. Part of this sale included a distribution of the buyer's stock to the then shareholders of Neogenix, but nowhere near the number of shares that these shareholders held in Neogenix.

    And to rub salt in their wounds, the buyer offered to sell its shares to the existing Neogenix shareholders.8

   The JOBS Act Doesn't Help

   The Jumpstart Our Business Startups Act (JOBS Act) passed in 2012 makes several changes to the securities laws that on their face appear to make the capital-raising process easier for startup companies. But it doesn't really help the small companies seeking capital through private placements without the use of SEC-registered broker-dealers. First, it provides an exemption from the requirement to register with the SEC as a broker-dealer for companies/finders that make or arrange private placements under SEC Rule 506 (sales to accredited investors, no general solicitations). However, that exemption is only from SEC and not state broker-dealer registration requirements, and the exemption is only available if the broker/finder does not receive any transaction-based compensation,e.g., based on sale of such securities.

The JOBS Act provides for crowdfunding. But the crowdfunding must be through an entity that is either registered with the SEC as a broker-dealer or crowdfunding portal and is also a member of FINRA.

    Second, the JOBS Act provides for crowdfunding. But the crowdfunding must be through an entity that is either registered with the SEC as a broker-dealer or crowdfunding portal and is also a member of the Financial Industry Regulatory Authority (FINRA). Neither the SEC nor FINRA have yet adopted, much less proposed, any rules regarding this registration process and the related rules governing the activities of such crowdfunding portals. In October 2012, the SEC in its publication of its rule-making agenda provided no time frame for the issuance of or proposal of such rules.

   Further, the JOBS Act prohibits the crowdfunding portal from compensating any promoter, finder or lead generators for providing it with information about potential investors, and amended the Securities Exchange Act to provide in the definition of a crowdfunding portal that it could not compensate employees, agents or others for soliciting or based on the sale of securities displayed or referenced on the crowdfunding portal's website.

      Dilemmas for Start-Ups

   What does all this mean for the startup and development stage company that badly needs capital? If you succeed, sooner or later you will have to either register your stock with the SEC, or have an audited financial statement and an opinion from counsel to get a major bank loan, when you sell out to a public company or go public yourself. As part of that process the sale of stock using unlicensed finders will be discovered, and will be reflected in a lower price or, worse yet, the bank, buyer or underwriter walking away from the potential liability.

   Neogenix is a perfect example of the decisions and dilemmas faced by every start-up company that is going to raise money and perhaps go public. (Other dilemmas include the decision to do PR and market or not and when, and included in that is what information to release to the public and analysts, and whether or not to listen to the Board of Advisors and/or Directors when their recommendations are dissimilar or outright contradictory to the path management wants to pursue). All along the way, advisors warned of problems but no one in the company listened, or merely brushed them off. Rational minds might have been overruled by others.

   The internal pressures to reach a liquidity milestone or event are enormous. The temptations to pursue shortcuts, legal, quasi-legal, and not legal at all are often overwhelming. In the race to reach these goals, shareholders, both internal and external, as well as the ultimate good of the company over the long run are often overlooked. Add in the arrogance of management, particularly scientist-founders, and the ingredients for a recipe guaranteed to cause indigestion (at the very least) after the meal are complete.

   In the current funding environment there is a lot of negativity expressed toward venture capitalists and the amount of control they want for their investment. However, in this example, had VCs been involved, the entire situation would have been avoided. Yes, certainly, there would have been other big issues. But the company would be further down the road toward proof-ofconcept and product or platform than they are today. Today, in-fighting over money and power takes precedence over the development of the company. Soon responsibility for decisions may be added to the mix if jail time or other substantial penalties become imminent.

   Everyday start-up companies are given good advice from internal or outside sources. It is up to them to choose the right road from the start. The question they must ask when they are desperate for money is, do I gamble and take a risk (always defined by the company as a shortcut) or do I do the right thing and delay gratification. The answer is often the key to the company's ultimate success.


  1. Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended Dec. 31, 2011, of Neogenix Oncology Inc. as filed on July 7, 2012 (2011 Form 10-K); Notification of Late Filing, Form 12b-25 for the period ended Sept. 30, 2011, filed by Neogenix Oncology Inc. Neogenix Oncology Inc. letter to shareholders dated June 29, 2012

  2. Neogenix Oncology Inc. 2011 Form 10-K. In 2004 after it originally issued its common stock to its founders, Neogenix made eight placements of stock totaling 958,000 shares. Four of these placements, totaling 521,000 shares for $521,000, were made through persons and entities that were not registered with the SEC or any state securities commission. In 2005 Neogenix sold 1,526,123 shares in 10 placements. Seven of these placements, totaling 941,123 shares and raising $1,172,248 were made using "finders." In 2006 it sold 481,966 shares in 13 placements. It made seven of these placements totaling 284,133 shares using finders and raised $822,399. In 2007 Neogenix sold 2,234,695 shares in 15 placements. It used finders in 10 placements. The finders sold 2,135,483 shares raising $7,195,670. In 2008 Neogenix sold 4,633,975 shares in 18 placements. It used finders in 12 placements to sell 2,139,725 shares raising $2,253,750. In 2009 it sold 1,949,183 shares in 13 placements. It used finders to make 12 placements totaling 3,196,058 shares and raised $10,103,265. In 2010 Neogenix sold 884,398 shares in 10 placements. It used finders to make all these placements raising $10,253,725. In 2011 Neogenix made four placements. It used finders to make three placements totaling 228,101 shares raising $14,817,550.

  3. Form 10 as filed by Neogenix Oncology Inc. with the Securities and Exchange commission on April 30, 2010.

  4. Neogenix Oncology Inc. 2011 Form 10-K. 5. Neogenix Oncology Inc. July 6, 2012, letter to shareholders, Neogenix Oncology Inc. 2011 Form 10-K.

  6. Neogenix Oncology Inc. 2011 Form 10-K. 7. Neogenix Oncology Inc. letter to shareholders of June 29, 2012.

  8. Neogenix Oncology Inc. Current Report on Form 8-K for Sept. 20, 2012.

Morris N. Simkin is a partner at McLaughlin & Stern. Sandra Holtzman is president and founder of Holtzman Communications, a marketing firm specializing in the life sciences. David Schmidt is a principal at Advanced Materials Advisory, a marketing and business development consulting company in Chester, N.J., that helps growing advanced technology companies.

Market research that actually gets to the point!

For further information, please view my recent webinar

Sandra Holtzman will be on a panel dealing with the 'Nuts and Bolts of setting up In New York'

Monday, November 16,

Is the 2009 UK Trade & Investment's (UKTI) Digital Mission: Hosting 25 UK IT companies at the British Consulate in NY. Sandra Holtzman will be on a panel dealing with the 'Nuts and Bolts of setting up In New York'

For further information, please visit

Sandra Holtzman is a Founder and Partner in new consultancy EHR Empowerment Consortium

Sandra Holtzman is a Founder and Partner in new consultancy EHR Empowerment Consortium

Sandra Holtzman is co-founder and partner in a new consultancy formed to help healthcare providers qualify for government stimulus monies through the American Recovery and Reinvestment Act - ARRA.

The organization is called EHR Empowerment Consortium (EHREC) and her partner and co-founder is Todd Frech. Together, through EMREC, they are able to offer clients a combined 50 years of background in healthcare information technology.

The EHR Empowerment Consortium will work with physicians and other healthcare providers (including chiropractors, midwives, DOs, etc.) and their practices to qualify for stimulus funds. As consultants, it will be Sandra and Todd’s job to create and oversee a smooth process for qualifying for these funds and the vetting and contracting of electronic medical record vendors.

Along with their teams Sandra and Todd will serve as the CIO for individual and small practices who may barely know they are eligible for funding and who usually don't have the time and expertise required to navigate the world of ARRA (American Recovery and Reinvestment Act) compliance. That means they will handle all the details that go with "meaningful use" and other compliance programs and performing due diligence with EMR vendors.

The EHR Empowerment Consortium has offices in New York City and Ravenel, South Carolina.

Both Sandra and Todd continue to provide services with their existing companies, Holtzman Communications, LLC and Ocius Medical Informatics, LLC respectively.

For more information, please contact Sandra at

Sandra Holtzman discusses “Don’t Be A Marketing Horror Show” at NJ Entrepreneurs Forum

NJEF's October 8th program features Sandra Holtzman, warning you to "Don't Be A Marketing Horror Story". Sandra literally wrote the book on the subject of marketing for early stage tech companies, and it's entitled "Ten Lies Startups Tell Themselves to Avoid Marketing". It's a great read and well worth your time. But come on Thursday October 8th from 4-6 p.m., and you'll gain so much more: inside information and the do's and don'ts of technology company marketing, the opportunity to meet your peers and learn what your competitors are doing.

See you on the 8th. Register now at

Sandra Holtzman spoke at the Genetic Engineering News annual sales conference.

She spoke on “Economics, Amoebas, and Imitators”.

Cornell University’s Startup Boot Camp features Sandra Holtzman on panel:

The Frontlines: Making the Pitch on June 4, 2009.

Holtzman Communications is on's Top U.S. Agencies

May 20, 2009
Holtzman Communications is on's Top U.S. Agencies from All Disciplines List Every year does an annual comprehensive listing of over 900 of the top ad agencies in the US. Holtzman Communications, LLC, a micro boutique agency that is independently held, moved up three positions from last year's standings. Sandra Holtzman, the President and owner of the agency, says that a significant contributor to the firm's continuing success, "is our ability to provide services and strategic thinking that increases our clients' exposure, brand, and ROI. It's important in any marketplace, but particularly critical in today's tough economic environment. We make every marketing dollar work harder than ever before."

She further states that one way the company does this is through their proprietary customer-focused qualitative market research methodology called OpenMind Research. Says Holtzman, "It's a highly cost-effective way for our customers to reach their market by helping their audience(s) reach them. After an OpenMind session, our clients have accurate and highly targeted marketing messaging that can be used in any medium."

Holtzman Communications is an award-winning advertising, marketing, interactive, branding, corporate and product image and positioning, and PR agency that specializes in all aspects of life sciences, Pharma, healthcare IT, IT, green/clean, consumer, B-to-B, and B-to-C spaces, from small start-ups to Fortune 500 companies. Sandra Holtzman, creative director and copywriter, founded the agency in 1997 after 15 years of success on Madison Avenue working with such clients as Merck, Warner-Lambert, Colgate, Johnson & Johnson, Acura car, Pfizer, Chesebrough-Ponds, New York Wine and Grape Counsel, Foot Joy golf shoes and gloves, Bury-Lu cookies, among others. The team consists of creative director-level art directors and copywriters, CIO-level programmers, information architects, media planners, account managers, market researchers, strategic and management consultants, among others.

The Morning X Live internet radio show featured Sandra Holtzman on April 8.

She discussed key marketing strategies that start up companies need in order to succeed.

What’s your value proposition and why is it important to your product/company?

Join our interactive panel as they build "value propositions" from real patent abstracts. With audience participation, the panel will determine real-life applications from some of the newest patents; (if you have a start up company, division or new product and would like us to work on your value proposition, please bring it in) identify potential benefits of those products and services, and create "90 second elevator pitches." With your help, we will separate features from benefits, address questions such as: what are the benefits of this new patented product or service, what is the best business model to use, and what support do you need to market or license it. Get key advice on the significance of branding, logos, and marketing, how to get the proposal past Legal - what information do you need so Legal understands what you want to get done, how to garner one's facts so Legal is more inclined to give the go-ahead, etc.

P.S. - This is an essential business development task for professional service firms!


Neil Schaffer
Neil Schaffer has served in executive management roles across a number of industries. Mr. Schaffer was the founder and since 2005 has served as CEO of Longview Consulting Group, a strategic advisory firm working with growing small and middle market businesses in the areas of marketing and financing strategy. Previously, he has led corporate operations, finance and administration while serving as EVP and CFO of two innovative technology companies in the advertising and media business – AudioAudit, Inc. (sold to Nielsen Media Research in 2005) and MediaPort, a technology consortium sponsored by Omnicom, Interpublic, and WPP Group.

Along with several former senior executives from Citicorp and three Ivy League computer science professors, he co-founded iPrivacy LLC, a software and services company focused on Internet privacy and security. Mr. Schaffer previously served as CFO of several industrial, distribution, and technology companies, including Horizon Paper Company, a leading paper brokerage firm; The Carson Group, Inc., a stock surveillance and financial information services company (sold to Thomson Financial); and The Hain Celestial Group (NASDAQ: HAIN), now the largest natural-products manufacturing company in the U.S.

Mr. Schaffer began his career as a certified public accountant with the middle-market practice group of Price Waterhouse in New York. He is a graduate of Binghamton University.

Sandra Holtzman
Sandra Holtzman is an award winning writer and strategist who founded Holtzman Communications, LLC in 1997. She has over 20 years of expertise in virtually every area of pharmaceutical advertising (ethical, OTC, DTC), nanotech, biotech, and chemical as well as emerging and converging technologies. She also has experience in business-to-business and consumer advertising.

In addition to being a co-chair of the NY Chapter of LES, Sandy has authored "Lies Startups Tell Themselves to Avoid Marketing" and lectures in the US and around the world on all aspects of strategic marketing including intellectual property, global, web development, and market research. Her company has development a proprietary methodology for customer-focused market research that helps companies communicate their value propositions fast and efficiently in today’s fast-paced marketing environment. She also writes for several journals on marketing and science subjects.

Thursday, October 2, 2008
5:15 to 7:30 PM

SCHEDULE: 5:15 pm: Networking session
6:00 pm: Panel discussion with Q&A
7:00 pm: Networking

Frankfurt Kurnit Klein & Selz PC
10th Floor Boardroom
488 Madison Avenue (between 51st and 52nd)
New York, NY 10022
Ph: (212)980-0120

LES Member: $50.00 by Sep 30, $55.00 at the door
Non-member: $60.00 by Sep 30, $65.00 at the door

Click HERE to register with interactive PDF form

For questions regarding registration please contact:

Curtis Gore
LES Membership & Chapter Coordinator
(703) 299-8209

For questions about the event contact:

Sandra Holtzman
LES Chapter Chair

DIRECTIONS to Frankfurt Kurnit Klein & Selz PC 488 Madison Avenue (between 51st and 52nd) Frankfurt Kurnit Klein & Selz' 10th Floor Boardroom is readily accessible by mass transit. You can easily walk from Grand Central Station at 42nd St. Or - You may take the #6 local IRT Lexington Avenue train to 51st Street and the E and V trains to the Lexington Avenue stop and walk about 3 blocks west.

Master Class 101 -- Doing Web 2.0 Business in the US – A roundtable sponsored by the British Consulate and UK Trade and Investment

On Monday, September 15, Sandra Holtzman will be at the roundtable with Heard Magazine, IBM, The Hatchery, Mayors Office -- International Division and Empire State Development Corporation. She represents Holtzman Communications and will discuss the following topics:

  • New ways to do market research that will give your company a competitive edge
  • How to market yourself in a saturated and competitive environment
  • Leveraging her expertise based on her book, LIES STARTUPS TELL THEMESELVES TO AVOID MARKETING
  • Hints about branding/marketing your company in the US

Past Events

Sandra Holtzman spoke about international marketing of life sciences at Shanghai Bio-forum conference

Sandra Holtzman spoke about international marketing of life sciences at the 13th Chinese Biopharmaceutical Association Conference and the 10th Shanghai International Forum on Biotechnology and Pharmaceutical Industry in Shanghai.

The FENG New York, NY Chapter

Next Meeting
When: Wednesday, 3/05/2008 5:30 PM to 8:30 PM

Where: Lee Hecht Harrison 200 Park Avenue (MetLife Building), 26th Floor 212-557-0009

Agenda: “Financial and Marketing Strategies for Start-Ups and Entrepreneurs”
Starting your own company as an entrepreneur requires considerable financial, marketing, and technical expertise. Many start-ups fail because their core competencies are too narrow; a novel idea or product alone does not spell success. In particular, many have difficultly raising sufficient capital to launch the initiative, or skimp on marketing under the false assumption that their novel concept will sell itself. Consequently, firms with considerable potential are often forced to close their doors not as a result of a flawed invention, but as a result of inadequate or faulty launch strategies.

The FENG New York has invited two experts in the start-up, entrepreneur, and angel investor fields to provide their insights into the various components of successful launch strategies. Doors open at 5:30, with speaker presentations beginning at 6:00. Both speakers will have the floor for up to 30 minutes, followed by a half hour of group Q&A. The networking hour begins at 7:30 and goes to 8:30. In order of speaking:

Michael Segal is the General Partner of Joshua Capital Partners, a private investment partnership. He is also founder of the boutique investment banking firm M.J. Segal Associates, which he created in 1987. M.J. Segal was formed to address the many problems faced by emerging/growth companies in accessing capital markets. In particular, these companies are often unable to raise capital through the large Wall Street firms. His firm actively focuses on developing relationships with institutional investors to find alternative sources of equity and debt capital for its clients, as well as create corporate strategies. His primary criticism of the investment process is that it tends to be unnecessarily complicated and tedious; thus his firm concentrates on developing realistic business plans and incubation time frames for its clients as they launch their initiatives. Michael is a member of the screening committee for the Tri-State Private Investors Network, one of the area’s leading Angel groups; and is a Founder of New York Private Equity Forums.

Sandra Holtzman founded Holtzman Communications, LLC in 1997. She is a marketing expert in the pharmaceutical industry, with expertise in several sectors including biotech, nanotech, chemical, and emerging and converging technologies. Her experience in this sector led her to co-author a recent book on marketing mistakes of emerging companies, entitled “Lies Start-Ups Tell Themselves to Avoid Marketing.” The book covers a wide range of managerial misconceptions and tactical errors that typically lead to the demise of entrepreneurial firms. Sandra will discuss the main points of the book, which will be on sale at the event. She also authored the marketing chapter of “A Comprehensive Guide to Business Incubation,” a top-selling book published by the National Business Incubation Association. Further, Sandra contributes as a columnist on a regular basis to the trade periodicals “Oncology Business Review” and “Lab to Wall Street.”

In order to attend this event please reply promptly to The FENG New York at, providing your name, preferred email address, and primary telephone number. After the meeting, this contact information will be circulated for networking purposes. A $20 cover charge for chapter administration is payable at the door. If your plans change and you are unable to attend, please provide notification so that another member can have your seat. As a matter of courtesy to the speakers, please turn off cell phones and do not leave the meeting until its conclusion.

Remember: The dress code is business casual.

Directions: From 45th Street entrance walk up one flight to 2nd floor check-in. From 42nd Street entrance walk through Grand Central Terminal, take escalators up two flights to 2nd Floor reception.

Navigating the startup road-- Thursday, October 11, at NJEF's Entrepreneur University sponsored by the NJ Entreprenurial Forum

Why is a business plan not enough without a marketing plan?

How do you identify the early adopters who will purchase your product?

These and other questions will be answered on October 11, 2007, from 4-6 p.m., at the CCIT when NJEF's Entrepreneur University hosts Sandra Holtzman at a special session of the Entrepreneurs Forum. Sandra will present the findings of her book, "Lies Start-ups Tell Themselves to Avoid Marketing" at the Commercialization Center for Innovative Technologies, at 675 Route 1 South, North Brunswick, NJ. Register in advance for $30 ($35 at the door) at the NJEF website, . Come for the good food and camraderie, stay for the networking and knowledge.

Sandra Holtzman will be giving a marketing seminar at University of Rochester School of Medicine December 4, 2007

Rochester Clinical & Translational Research Curriculum Seminar Announcement
December 4, 2007

The Truth About Marketing a Startup Business

Sandra Holtzman recently spoke at the Rochester Chapter of the Licensing Executives Society.

"Lies Startups Tell Themselves to Avoid Marketing" presented by Sandra Holtzman President, Holtzman Communications, LLC Lead Co-Chair, New York City Chapter of Licensing Executive Society

Lite luncheon will be served. Please join us! @ 12:15 - 1:15pm LeChase Assembly (G9576)

LeChase Assembly is in the Arthur Kornberg Medical Research Building, just past the Coffee Shop in the Atrium on the ground floor, then through the double doors.

Panelist at the World Intellectual Property Organization (WIPO) Licensing Training Program: Protection, Marketing and Licensing Research Results

Organized by The World Intellectual Property Organization (WIPO) in cooperation with The University of West Indies (UWI), The Scientific Research Council of Jamaica (SRC), The Jamaica Intellectual Property Office (JIPO), and The Jamaica Promotions Corporation (JAMPRO).

The main objective of this event was to empower technology managers in research institutions and the private sector to value and protect their intellectual property assets, to identify opportunities and risks in licensing agreements, and to negotiate successful technology licensing agreements.

Focus on Canadian Life Sciences and IT Companies

Endorsed by the University of Manitoba's Technology Transfer Office

"Lies That SMEs & StartUps Tell Themselves to Avoid Marketing!" and overcoming barriers for Canadian companies entering the US market were the subjects of Sandra Holtzman's presentation to the Health Care Products Association of Manitoba at The Hotel Fort Garry, Winnipeg, Manitoba. As a result, her company was endorsed by the University of Manitoba's Technology Transfer Office.

Appeared at New Jersey Biomedical Engineering Showcase

Sandra Holtzman will be selling and signing her new book "Lies Startups Tell Themselves to Avoid Marketing" at the 4th Annual New Jersey Biomedical Engineering Showcase at the New Jersey Institute of Technology (NJIT) Campus Center Ballroom (second floor), Newark, New Jersey.

Sponsors include NJIT, Rutgers-The State University of New Jersey, Princeton University, The University of Medicine and Dentistry of New Jersey, Stevens Institute of Technology, Kean University, the Public Health Research Institute of Technology, The Biotechnology Council of New Jersey, The New Jersey Commission on Science and Technology, The New Jersey Commission on Spinal Cord Research, the HealthCare Institute of New Jersey, and the Biomedical Engineering Alliance for Industrial Internships.

This year's theme is Biomedical Engineering Innovation – from Concept to Clinic to Commerce. The program includes keynote panels exploring the topics of technology commercialization, New Jersey State support for the Bio/Life Sciences Cluster and global perspectives and success stories on translational research.

Planting New Ideas at BioStrategy Partners First Sightings 2007

Sandra Holtzman will be speaking and signing her new book, "Lies Startups Tell Themselves to Avoid Marketing", at BioStrategy Partners' First Sightings 2007 in Princeton, NJ. "Resources, Challenges, and Opportunities for Emerging Life Sciences Companies" is a mentoring and networking program for pre-seed and seed-stage life sciences companies in New Jersey, Pennsylvania, and Delaware.

First Sightings is a coaching process and networking opportunity for emerging life sciences companies. BioStrategy Partners provides discovery, pre-seed, and seed life sciences companies with the tools to help them grow their businesses to the next level.

Hatching the Right Companies at the NBIA Annual Meeting

Holtzman Communications was a participating sponsor at the National Business Incubation Association's 21st International Conference on Business Incubation in Seattle, Washington. NBIA is the world's leading organization advancing business incubation and entrepreneurship. This meeting provided thousands of professionals with the information, education, advocacy, and networking resources to bring excellence to the process of assisting early-stage companies worldwide.